BetaFor now, only select medications are available to compare. This data is sourced from the medication label and is not exhaustive.
efficacy
ACR20 Response at Week 12
cDMARD-IR: 66%; TNFi-IR: 49%
cDMARD-IR: 64%; bDMARD-IR: 65%
ACR50 Response at Week 12
cDMARD-IR: 34%; TNFi-IR: 20%
cDMARD-IR: 38%; bDMARD-IR: 34%
DAS28-CRP <2.6 at Week 12
cDMARD-IR: 26%; TNFi-IR: 11%
cDMARD-IR: 31%; bDMARD-IR: 29%
Review efficacy data to choose the clinically appropriate treatment for your patient
safety
Black Box Warning
Yes
Yes
Contraindications
None
Known hypersensitivity to upadacitinib or excipients
Most Common Adverse Reactions (≥1%)
In RA: upper respiratory tract infection, nausea, herpes simplex, herpes zoster
In RA: upper respiratory tract infection, herpes zoster, herpes simplex, bronchitis, nausea, cough, pyrexia, acne, headache
indications
Adult Rheumatoid Arthritis
Yes
Yes
COVID-19 (hospitalized, requiring oxygen)
Yes
No
Alopecia Areata
Yes
No
Psoriatic Arthritis
No
Yes
Ulcerative Colitis
No
Yes
Crohn’s Disease
No
Yes
Atopic Dermatitis
No
Yes
Axial Spondyloarthritis / Ankylosing Spondylitis
No
Yes
Juvenile Idiopathic Arthritis (Polyarticular, PsA, ERA)
No
Yes (≥2 years, weight-based dosing)
Giant Cell Arteritis
No
Yes
Coverage
Add insurance carrier above to get more details about the coverage for each medication
dosing
Standard Dosing
2 mg once daily orally, with or without food
15 mg once daily (monotherapy or with cDMARDs)
Renal Impairment Dosing
Mild: 2 mg once daily; Moderate: 1 mg once daily; Severe: not recommended
No adjustment needed (mild–severe)
Hepatic Impairment Dosing
Mild or Moderate: no adjustment; Severe: not recommended
Mild or moderate: no adjustment; Severe: not recommended
pharmacology
Mechanism of Action
JAK1/2 inhibitor with some TYK2 activity
Selective JAK1 inhibitor
Half-life
12–16 hours
8–14 hours
Time to Peak
1 hour
2–4 hours (ER tablet)
Bioavailability
~80%
Not specified
Find savingsView All Programs
Coverage Not Required
$25Olumiant (baricitinib)
No data available
Alternative Drug Suggestions